Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase I for Fallopian Tube Cancer. According to GlobalData, Phase I drugs for Fallopian Tube Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Luveltamab tazevibulin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Luveltamab tazevibulin overview
STRO-002 is under development for the treatment of solid tumors, relapsed/refractory cancers like epithelial ovarian cancer, endometrial carcinoma, fallopian tube cancer, peritoneal cancer, non-small cell lung cancer, triple negative breast cancer, adenocarcinoma and relapsed/refractory rare pediatric acute myeloid leukemia (AML). It is administered through intravenous route. It is developed based on Xpress CF plus platform technology. The drug candidate is a potent and Sutro proprietary hemia-sterlin derivative warhead. It is a monoclonal antibody conjugate that acts by targeting folate receptor alpha (FolR alpha).
See Also:
Sutro Biopharma overview
Sutro Biopharma is a clinical-stage oncology company. It develops next-generation cancer therapeutics which include antibody-drug conjugates (ADCs), bispecific antibodies, cytokine-based immuno-oncology therapies and vaccines through the XpressCF and XpressCF+ platforms. The company’s pipeline products include STRO-001 to treat B-cell malignancies; STRO-002, luvelta treats ovarian cancer, endometrial cancer, adenocarcinoma, non-small cell lung cancer, GLlS2 pediatric acute myeloid leukemia; STRO-003 treats solid tumors, hematological cancers, STRO-004 treat solid tumors, VAX-24, MK-1484 treats invasive pneumococcal disease and metastatic solid tumors. It works in collaboration with Merck & Co., Inc and Astellas Pharma Inc., among others. Sutro Biopharma is headquartered in South San Francisco, California, the US.
For a complete picture of Luveltamab tazevibulin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
